A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by OncoMed Pharmaceuticals, Inc.
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
First received: January 24, 2013
Last updated: July 17, 2015
Last verified: July 2015
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Condition Intervention Phase
Relapsed or Refractory Solid Tumors
Drug: OMP-52M51
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Resource links provided by NLM:

Further study details as provided by OncoMed Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Safety profile of OMP-52M51 in subjects with relapsed or refractory solid tumors [ Time Frame: Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics (PK) of OMP-52M51 in subjects with relapsed or refractory solid tumors [ Time Frame: PK analyses at various time points following the 1st and 2nd doses, immediately pre and post-dose for all subsequent doses at treatment term, every 4 weeks after discontinuation of study drug or 12 weeks ] [ Designated as safety issue: No ]
    Apparent half life, AUC, clearance, volume of distribution

  • Immunogenicity [ Time Frame: Assessed at baseline, prior to each dose, at treatment termination and every 4 weeks after the discontinuation of the study drug for 12 weeks. ] [ Designated as safety issue: No ]
  • Preliminary Efficacy [ Time Frame: Evaluation for response will be assessed on day 70 of study and every 8 weeks (or 9 weeks for Q3W schedule) thereafter and will be based on RECIST v1.1. ] [ Designated as safety issue: No ]

Estimated Enrollment: 33
Study Start Date: February 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OMP-52M51 Drug: OMP-52M51


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for the study:

  1. Age >18 years
  2. ECOG performance status <2 (see Appendix B)
  3. Solid tumor malignancy for which there is no remaining standard therapy or either refuse or are not considered to be candidates for any remaining standard therapy.
  4. Must have a tumor that is measurable or evaluable per RECIST v1.1 in the dose escalation phase. In the expansion cohort(s), subjects must have measurable disease.
  5. Subjects must have Formalin-Fixed, Paraffin-Embedded (FFPE) tissue available either archived or fresh core or punch needle biopsied at study entry (two fresh cores/punches preferred whenever possible) for determination of Notch1 pathway activation status.
  6. Must have received their last chemotherapy, biologic, radiotherapy, or investigational therapy at least 4 weeks prior to enrollment; 6 weeks if the last regimen included BCNU or mitomycin C.
  7. Subjects must have normal organ and marrow function as defined below:

    • Absolute neutrophil count >1500/mL without growth factor support in the past 7 days
    • Platelets >100,000/mL without transfusions in the past 7 days
    • Total bilirubin <1.5 X institutional upper limit of normal (ULN) (<2X ULN for subjects with Gilbert's syndrome)
    • AST (SGOT) and ALT (SGPT) <3 X institutional ULN (for subjects with hepatic involvement <5 X institutional ULN but cannot be associated with elevated bilirubin)
    • PT/INR and aPTT within 1.5 X institutional ULN
    • Creatinine <1.5 X institutional ULN OR
    • Creatinine clearance >60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
    • Normal Ejection Fraction (>50%) on ECHO scan or MUGA
  8. Women of childbearing potential must have had a prior hysterectomy or have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug. Men must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and from study entry through at least 6 months after discontinuation of study drug. Should a woman enrolled in the study or a female partner of a man enrolled in the study become pregnant or suspect she is pregnant while participating in this study or within 6 months after discontinuation of study, she should inform the Investigator immediately.
  9. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible for participation in the study:

  1. Currently receiving any therapeutic treatment for their malignancy including other investigational agents
  2. Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors
  3. Uncontrolled seizure disorder, active neurologic disease, or active CNS involvement except for individuals who have previously-treated CNS metastases, are asymptomatic, and have no requirement for higher doses of corticosteroids (> prednisone 10mg orally per day) or anti-seizure medication for at least 4 weeks prior to first dose of study drug.
  4. History of a Grade 4 allergic reaction attributed to humanized or human monoclonal antibody therapy
  5. Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  6. Pregnant women or nursing women
  7. Ongoing malignancies or malignancies in remission <3 years other than the malignancies included in this trial. Patients with history of known squamous cell skin cancers within the past 3 years will not be included in this trial. The following prior malignancies are allowable irrespective of when they occurred: in situ carcinoma of the cervix, in situ ductal breast cancer, and low-grade local bladder cancer.
  8. Subjects with known HIV infection
  9. Known bleeding disorder or coagulopathy
  10. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.
  11. Hemoptysis in excess of 2.5 mL(or one-half teaspoon) within 8 weeks of first dose of study drug.
  12. Subjects receiving heparin, warfarin, or other similar anticoagulants, except for subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.
  13. New York Heart Association Classification II, III, or IV (see Appendix D)
  14. Subjects with poorly controlled blood pressure (defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is not responsive to medical therapy. Subjects taking antihypertensive medications must be taking ≤2 medications to obtain this level of blood pressure control.

    NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry.

  15. Subjects with ECG evidence of ischemia or ≥Grade 2 ventricular arrhythmia, subjects who have a history of acute myocardial infarction within 6 months, or subjects with unstable angina.
  16. Subjects with known clinically significant gastrointestinal disease including, but not limited to:

    • inflammatory bowel disease
    • active peptic ulcer disease
    • known intraluminal metastatic lesion(s) with risk of bleeding
    • history of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
  17. Subjects with diarrhea at time of enrollment or have an ongoing requirement for anti diarrheal therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01778439

United States, California
University of California, San Francisco/Helen Diller Cancer Institute Recruiting
San Francisco, California, United States, 94115
Contact: Pamela Munster, MD    415-353-7287    pmunster@medicine.ucsf.edu   
Principal Investigator: Pamela Munster, MD         
United States, Colorado
University of Colorado Denver -RCI-South Tower Recruiting
Aurora, Colorado, United States, 80045
Contact: Gail Eckhardt, M.D.    303-724-3850      
Principal Investigator: Gail Eckhardt, M.D.         
United States, Michigan
Karmanos Cancer Institute (KCI) Recruiting
Detroit, Michigan, United States, 48201
Contact: Anthony Shields, MD    313-576-8735    shieldsa@karmanos.org   
Principal Investigator: Anthony Shields, MD         
Wayne State University/Oncology Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Patricia LoRusso, DO    313-576-8716      
Principal Investigator: Patricia M LoRusso, DO         
United States, Texas
T he University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Renata Ferrarotto, MD    713-745-6774    rferrarotto@mdanderson.org   
Principal Investigator: Renata Ferrarotto, MD         
South Texas Accelerated Research Therapeutics, LLC Recruiting
San Antonio, Texas, United States, 78229
Contact: Amita Patnaik, M.D.    210-593-5270      
Principal Investigator: Amita Patnaik, M.D.         
Sponsors and Collaborators
OncoMed Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: OncoMed Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01778439     History of Changes
Other Study ID Numbers: 52M51-002
Study First Received: January 24, 2013
Last Updated: July 17, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by OncoMed Pharmaceuticals, Inc.:
Phase 1
Dose escalation
relapsed or refractory
solid tumor

ClinicalTrials.gov processed this record on November 25, 2015